{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:37:04Z","timestamp":1793137024597,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jchf.2024.11.013","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:04:44Z","timestamp":1738591484000},"page":"358-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Wever-Pinzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5642-2112","authenticated-orcid":false,"given":"Wael","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2592-136X","authenticated-orcid":false,"given":"Jonathan","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Carter-Bonanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.jchf.2024.11.013_bib1","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.013_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jchf.2024.11.013_bib3","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.11.013_bib4","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjcard.2023.10.074","article-title":"Medical treatment strategies\u00a0for hypertrophic cardiomyopathy","volume":"212S","author":"Hutt","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2024.11.013_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pcad.2023.08.006","article-title":"Medical therapies for hypertrophic cardiomyopathy: Current state of the art","volume":"80","author":"Desai","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"16","key":"10.1016\/j.jchf.2024.11.013_bib6","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME)","volume":"68","author":"Gentry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2024.11.013_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jchf.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.jchf.2024.11.013_bib10","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.013_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168407","article-title":"A\u00a0small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jchf.2024.11.013_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10253","key":"10.1016\/j.jchf.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jchf.2024.11.013_bib14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.013_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.013_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32\u00a0weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jchf.2024.11.013_bib17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"25","key":"10.1016\/j.jchf.2024.11.013_bib18","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.013_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"10293","key":"10.1016\/j.jchf.2024.11.013_bib20","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2024.11.013_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017185","article-title":"Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM trial","author":"Desai","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.013_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2024.06.025","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in VALOR-HCM trial","volume":"84","author":"Desai","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.11.013_bib23","doi-asserted-by":"crossref","unstructured":"Desai MY, Okushi Y, Wolski K, et\u00a0al. Mavacamten-associated temporal changes in left\u00a0atrial function in obstructive HCM: insights from the VALOR-HCM trial. JACC Cardiovasc Imaging. Published online September 2, 2024. https:\/\/doi.org\/10.1016\/j.jcmg.2024.08.005","DOI":"10.1016\/j.jcmg.2024.08.005"},{"issue":"47","key":"10.1016\/j.jchf.2024.11.013_bib24","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.jchf.2024.11.013_bib25","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jchf.2024.11.013_bib26","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jchf.2024.11.013_bib27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.013_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.medj.2024.06.001","article-title":"Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy","volume":"5","author":"Desai","year":"2024","journal-title":"Med"},{"issue":"8","key":"10.1016\/j.jchf.2024.11.013_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.013_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2024.11.013_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pcad.2023.06.001","article-title":"Patient reported outcomes in obstructive hypertrophic cardiomyopathy undergoing myectomy: results from SPIRIT-HCM study","volume":"80","author":"Tower-Rader","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.013_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jchf.2022.09.012","article-title":"Functional and symptomatic clinical trial endpoints: the HFC-ARC Scientific Expert Panel","volume":"10","author":"Psotka","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.jchf.2024.11.013_bib33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ahj.2015.02.006","article-title":"Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography","volume":"169","author":"Masri","year":"2015","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.013_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in\u00a0hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.jchf.2024.11.013_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcmg.2013.08.010","article-title":"Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes","volume":"7","author":"Desai","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"21","key":"10.1016\/j.jchf.2024.11.013_bib36","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a\u00a0disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.013_bib37","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtcvs.2020.12.016","article-title":"Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy","volume":"164","author":"Cui","year":"2022","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"6","key":"10.1016\/j.jchf.2024.11.013_bib38","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.jchf.2024.11.013_bib39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0735-1097(01)01778-8","article-title":"Long-term outcome in patients with apical hypertrophic cardiomyopathy","volume":"39","author":"Eriksson","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jchf.2024.11.013_bib40","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.amjcard.2013.02.040","article-title":"Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy","volume":"111","author":"Klarich","year":"2013","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jchf.2024.11.013_bib41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10554-021-02430-w","article-title":"Clinical, echocardiographic and cardiac MRI predictors of outcomes in patients with apical hypertrophic cardiomyopathy","volume":"38","author":"Yin","year":"2022","journal-title":"Int J Cardiovasc Imaging"},{"issue":"30","key":"10.1016\/j.jchf.2024.11.013_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci Adv"},{"issue":"11","key":"10.1016\/j.jchf.2024.11.013_bib43","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J\u00a0Card Fail"},{"issue":"21","key":"10.1016\/j.jchf.2024.11.013_bib44","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jchf.2024.11.013_bib45","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00228-024-03660-2","article-title":"Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients","volume":"80","author":"Tanashat","year":"2024","journal-title":"Eur J Clin Pharmacol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177924008783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T12:35:45Z","timestamp":1740659745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177924008783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2213177924008783"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.013","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.09.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2024.11.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}